Social Media in the Pharmaceutical Industry

SMi Group22 - 23 January 2018, London, UK.
Social media is the perfect channel for pharmaceutical companies to educate, market, listen and connect with customers, patients and physicians. How the pharmaceutical industry utilize social media is particularly complex as regulators such as the FDA have not yet written the rules about how pharmaceuticals can engage with potential customers and patients.

Join SMi's 10th Annual Social Media in the Pharmaceutical Industry Conference to learn the best way your company can benefit from social media. Hear from industry experts on how to leverage social media platforms to develop a robust digital strategy and discuss the latest challenges and techniques in the field of 'social pharma'.

How Will You Benefit?

Network and learn from leading professionals such as:
  • Emma Sutcliffe, Director, Patient Engagement & Innovation, NexGen Healthcare
  • Tughan Demirbilek, Strategy & Operations Director, Bristol-Myers Squibb
  • Marcel Gmünder, Global Head, Digital Health Group, Roche Diabetes Care
  • Elodie Douangmanivanh, Head of Digital Services, MSD
  • Sebastian Soithongsuk, Global Content Manager Digital Comms, GSK
  • Aslihan Unal, Digital Strategy Group Manager, Janssen
  • Hervé Dumas, Patients’ Technology Solutions Lead, UCB
  • Sarah Holiday, Social Media Strategy Lead, Pfizer

Some Featured Highlights will include:

  • Hear how Janssen create powerful pharmaceutical social media strategies enabling patient engagement.
  • Learn how to build integrated, impactful social media strategies with Pfizer.
  • Discuss the potential of wearable technologies creating behavioural changes for patients with UCB.
  • Discover with GSK how to make your social media content less "promotional" and more about storytelling.
  • Examine how Bristol Myers-Squibb create an excellent digital strategy whilst engaging patients.

For further information and to register, please visit:
http://www.social-media-pharma.com/wpn

Early-Bird Rates

  • Book by 31st October and save £200
  • Book by 30th November and save £100

About SMi Group
The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

FDA grants priority review to Roche's cancer immun…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) a...

Kymriah® (tisagenlecleucel), first-in-class CAR-T …

Novartis today announced the US Food and Drug Administration (FDA) has approved Kymriah® (tisagenlecleucel) suspension for intravenous infusion for its second indication ...

Daily aspirin linked to higher risk in men

Men who take once-daily aspirin have nearly double the risk of melanoma compared to men who are not exposed to daily aspirin, reports a new Northwestern Medicine study. W...

New leads on treating dementia and Alzheimer's

A new research study by scientists in Australia and the US provides an explanation for why clinical trials of drugs reducing proteins in the brain that were thought to ca...

Boehringer Ingelheim R&D pushes to transcend d…

Family-owned pharmaceutical company Boehringer Ingelheim has presented its latest pipeline updates at a Research & Development press conference entitled 'Transcending Dis...

Roche reports a strong start in 2018

Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that in the first three months of 2018, Group sales rose 6% to CHF 13.6 billion. Sales in the Pharmaceuticals Division in...

Novartis launches FocalView app, providing opportu…

Novartis announced the launch of its FocalView app, an ophthalmic digital research platform created with ResearchKit. FocalView aims to allow researchers to track disease...

To treat pain, you need to treat the patient

People in chronic pain are some of the most difficult patients to treat. They have complex circumstances that medicine can't always remedy. Pain can be amplified, by depr...

A potential new weapon in the addiction battle: FD…

Cocaine and other drugs of abuse hijack the natural reward circuits in the brain. In part, that's why it's so hard to quit using these substances. Moreover, relapse rates...

Novo Nordisk participates in new research project …

Within the newly started European research project Hypo-RESOLVE, 23 leading international players from academia, industry and civil society have joined forces to find bet...

Chemical octopus catches sneaky cancer clues, trac…

Cancer drops sparse chemical hints of its presence early on, but unfortunately, many of them are in a class of biochemicals that could not be detected thoroughly, until n...

Alcon Cares Project 100 commits to reducing catara…

Alcon, the global leader in eye care and a division of Novartis, has announced Alcon Cares Project 100, which aims to reduce cataract blindness by providing equipment to ...